Plasma proteomic biomarkers predict therapeutic responses in advanced biliary tract cancer patients receiving Camrelizumab plus the GEMOX treatment

Shiyun Cui(Nanjing General Hospital of Nanjing Military Command), Xiaofeng Chen(Jiangsu Cancer Hospital), Yitong Tian(Nanjing Medical University), Qiuyu Wu(Nanjing Medical University), Xiangcheng Li(Nanjing Medical University), Yucheng Cai(Nanjing Medical University), Hao Qian(Nanjing Medical University), Xinyi Zhang(Hunan University of Traditional Chinese Medicine), Lei Fan(UNSW Sydney), Rong Wang(Bayer (United States)), Yiyang Xu(Nanjing Medical University), Xiaofeng Wu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuting Ding(Nanjing Medical University), Weici Liu(Nanjing Medical University), Jiaguang Zhang(Nanjing Medical University)
npj Precision Oncology
April 7, 2025
Cited by 4


Related Papers